NYSE:CHE - Chemed Stock Price, Forecast & News

Chemed trades on the New York Stock Exchange (NYSE) under the ticker symbol "CHE."

Chemed announced a quarterly dividend on Friday, November 1st. Stockholders of record on Monday, November 11th will be paid a dividend of $0.32 per share on Monday, December 2nd. This represents a $1.28 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, November 7th. View Chemed's Dividend History.

Chemed announced that its board has authorized a share repurchase plan on Wednesday, March 7th 2018, which permits the company to repurchase $150,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its stock is undervalued.

Chemed Co. (NYSE:CHE) posted its quarterly earnings data on Tuesday, October, 29th. The company reported $3.46 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $3.31 by $0.15. The company earned $480.61 million during the quarter, compared to analysts' expectations of $478.89 million. Chemed had a net margin of 11.14% and a return on equity of 35.06%. The firm's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same quarter last year, the firm earned $3.07 earnings per share. View Chemed's Earnings History.

Chemed is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Chemed.

Chemed will be holding an earnings conference call on Tuesday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 equities research analysts have issued twelve-month price targets for Chemed's stock. Their forecasts range from $405.00 to $500.00. On average, they anticipate Chemed's share price to reach $466.25 in the next year. This suggests that the stock has a possible downside of 2.6%. View Analyst Price Targets for Chemed.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemed in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chemed.

Media headlines about CHE stock have been trending somewhat positive on Thursday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chemed earned a news impact score of 1.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Chemed.

Chemed saw a decline in short interest in the month of December. As of December 13th, there was short interest totalling 211,300 shares, a decline of 18.0% from the November 28th total of 257,700 shares. Based on an average daily trading volume, of 89,500 shares, the days-to-cover ratio is currently 2.4 days. Approximately 1.4% of the company's shares are short sold. View Chemed's Current Options Chain.

Some companies that are related to Chemed include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Amedisys (AMED), LHC Group (LHCG), AMN Healthcare Services (AMN), BioScrip (BIOS), MEDNAX (MD), CorVel (CRVL), R1 RCM (RCM), Tivity Health (TVTY), The Providence Service (PRSC), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemed investors own include Home Depot (HD), Altria Group (MO), AT&T (T), AbbVie (ABBV), CVS Health (CVS), Chevron (CVX), Walt Disney (DIS), Enterprise Products Partners (EPD), Occidental Petroleum (OXY) and Boeing (BA).

Chemed's stock is owned by a number of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (2.29%), Boston Trust Walden Corp (0.75%), TSP Capital Management Group LLC (0.13%), Nisa Investment Advisors LLC (0.07%), Decatur Capital Management Inc. (0.06%) and Hanson & Doremus Investment Management (0.03%). Company insiders that own Chemed stock include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Nicholas Michael Westfall, Patrick P Grace, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Institutional Ownership Trends for Chemed.

CHE stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Campbell & CO Investment Adviser LLC, Nisa Investment Advisors LLC, NEXT Financial Group Inc, State of Alaska Department of Revenue, Decatur Capital Management Inc., Hanson & Doremus Investment Management and TrimTabs Asset Management LLC. Company insiders that have sold Chemed company stock in the last year include David Patrick Williams, Donald E Saunders, Frank E Wood, George J Walsh III, Kevin J Mcnamara, Michael D Witzeman, Naomi C Dallob, Spencer S Lee, Thomas P Rice and Walter L Krebs. View Insider Buying and Selling for Chemed.

CHE stock was purchased by a variety of institutional investors in the last quarter, including Boston Trust Walden Corp, Janney Montgomery Scott LLC, AE Wealth Management LLC, Calamos Advisors LLC, Private Trust Co. NA, Ambassador Advisors LLC, First Hawaiian Bank and Exane Derivatives. Company insiders that have bought Chemed stock in the last two years include Donald E Saunders and George J Walsh III. View Insider Buying and Selling for Chemed.

Shares of CHE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHE stock can currently be purchased for approximately $478.86.

Chemed has a market capitalization of $7.67 billion and generates $1.78 billion in revenue each year. The company earns $205.54 million in net income (profit) each year or $11.93 on an earnings per share basis. Chemed employs 15,707 workers across the globe.View Additional Information About Chemed.

The official website for Chemed is http://www.chemed.com/.

Chemed's mailing address is 255 EAST FIFTH STREET SUITE 2600, CINCINNATI OH, 45202. The company can be reached via phone at 513-762-6690.